Skip to content

Castle Biosciences CSTL Finance Lease, Principal Payments

Finance Lease, Principal Payments at other companies

Fulgent Genetics, Inc. logo
Fulgent Genetics, Inc.FLGT
GeneDx Holdings logo
GeneDx HoldingsWGS
BillionToOne, Inc.
 logo
BillionToOne, Inc. BLLN

Other financials

Income statement

See full
Revenue$83.7M-4.9%
Gross profit$63.1M-11.8%
Operating income-$18.4M+34.1%
Net income-$14.5M+43.8%
EPS (diluted)-$0.49+45.6%

Balance sheet

See full
Cash & equivalents$63.8M-28.9%
Total debt$36.7M+42.1%
Total equity$461.4M+4.8%
Total assets$547.8M+9.2%

Cash flow

See full
Operating cash flow-$22.1M-267%
CapEx$12.5M+163%
Free cash flow-$34.6M-221%

Valuation

See full
Market cap$694.86M+29.9%
Enterprise value$667.82M+41.8%
P/S+0.5×

Profitability

See full
Gross margin77.9%-4.1pp
Operating margin-9.8%-30.8pp
Net margin-3.8%-10.2pp
FCF margin1.3%-10.7pp

Returns & leverage

See full
Return on equity-2.8%-10.6pp
Debt / equity0.1×0.0×
Current ratio6.7×-2.6×

Where this comes from

Reported directly by Castle Biosciences in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeasePrincipalPayments.

The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Castle Biosciences's finance lease, principal payments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Castle Biosciences's finance lease, principal payments?
Castle Biosciences (CSTL) reported finance lease, principal payments of $24K in Q1 2026.
How has Castle Biosciences's finance lease, principal payments changed year-over-year?
Castle Biosciences's finance lease, principal payments decreased by 7.7% year-over-year, from $26K to $24K.
What is the long-term trend for Castle Biosciences's finance lease, principal payments?
Over 4 years (2021 to 2025), Castle Biosciences's finance lease, principal payments has grown at a 94.7% compound annual growth rate (CAGR), from $8K to $115K.